Schedule of Changes in the Liability Related to the Sale of Future Royalties (Details) - USD ($) $ in Thousands		12 Months Ended
	Jun. 07, 2022	Dec. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Liability related to sale of royalties, beginning balance		$ 31,045
Proceeds from sale of royalties, net of transaction costs			$ 33,900
Proceeds from milestone payments, net of transaction costs		9,500
Non-cash interest expense		3,416	5,772
RUXIENCE royalties paid by Pfizer to HCR		(6,779)	(8,627)
Gain from extinguishment of liability related to sale of royalties	$ (37,200)	$ (37,182)
Liability related to sale of royalties, ending balance			31,045
Current portion of liability related to sale of royalties			(15,465)
Liability related to sale of royalties, non-current			$ 15,580